advertisement
Starr MR 17
Showing records 1 to 17 | Display all abstracts from Starr MR104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Starr MR
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Shah SM
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Huang D
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Boopathiraj N
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Wong JC
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Starr MR; Dalvin LA
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Patel LG; Ammar M
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
AbouChehade J
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Hsu J
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Damento G; Garcia MD
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Sivalingam A; Mehta S
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Hodge DO; Bakri SJ
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Ho AC
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Sit AJ
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Kuriyan AE; Khan MA
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
104853 Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Iezzi R
American Journal of Ophthalmology 2022; 243: 98-108
104926 Prevalence, characteristics, and outcomes of rhegmatogenous retinal detachment in eyes with trabeculectomy or glaucoma drainage devices
Cohen MN; Xu D; Lee D; Moster MR; Yonekawa Y
Retina (Philadelphia, Pa.) 2022; 42: 2039-2045
